Table 1.
Dosage, clinical trials and treated diseases of approved BtkIs.
| Drug | Dosage | Diseases | Number of Clinical Trials | ||
|---|---|---|---|---|---|
| Total | GVHD | COVID-19 | |||
| Ibrutinib | 420 mg/day (CLL/SLL, WM) 560 mg/day (MCL, MZL) |
CLL/SLL WM MZL MCL cGVHD |
358 | 9 (1 completed, 5 in recruitment, 2 actives not recruiting, 1 enrolling by invitation) | 2 (NCT04375397 in recruitment; NCT04665115 not recruiting) |
| Acalabrutinib | 100 mg b.i.d. | CLL/SLL MCL |
99 | 2 (NCT04198922, NCT04716075, in recruitment) | 3 (NCT04497948 terminated, NCT04380688 completed, NCT04346199 active not recruitment) |
| Zanubrutinib | 160 mg b.i.d. | MCL | 49 | none | 1 (NCT04382586 in recruitment) |